既往暴露于肿瘤坏死因子抑制剂的银屑病关节炎患者中二线生物制剂的长期持续性:基于法国医疗保险数据库(SNDS)的全国队列研究
该全国队列研究纳入2015—2020年间停用肿瘤坏死因子抑制剂(TNFi)后启用二线生物制剂的成人银屑病关节炎(PsA)患者2975例,比较不同类别生物制剂的长期持续性。总体1年和3年持续率分别为42%和17%;校正后,IL-17抑制剂(RRa 0.79,95%CI 0.71~0.87)和IL-12/23抑制剂(RRa 0.69,95%CI 0.61~0.79)的持续性与TNFi相比更高,IL-12/23抑制剂与IL-17抑制剂之间无显著差异(RRa 0.88,95%CI 0.76~1.02)。
要点
- 停用TNFi后启用二线生物制剂的PsA患者中,总体1年和3年持续率分别为42%和17%。
- 校正后,IL-17抑制剂(RRa 0.79,95%CI 0.71~0.87)和IL-12/23抑制剂(RRa 0.69,95%CI 0.61~0.79)的持续性与TNFi相比更高。
- IL-12/23抑制剂与IL-17抑制剂之间的持续性无显著差异(RRa 0.88,95%CI 0.76~1.02)。
核心结论
- 真实世界研究显示,既往暴露于TNFi的PsA患者中所有生物制剂在3年时的持续性均较低,但IL-17抑制剂或IL-12/23抑制剂的持续性高于TNFi。
研究设计与样本
- 法国全国队列研究,纳入2015—2020年间停用TNFi后启用二线生物制剂的成人PsA患者2975例,数据来自法国医疗保险行政医疗数据库并链接医院出院数据库。
主要发现
- 1580例(53%)启用第二种TNFi,426例(14%)启用IL-12/23抑制剂,969例(33%)启用IL-17抑制剂。
- 总体1年和3年持续率分别为42%和17%。
- 校正后,与TNFi相比,IL-17抑制剂的校正相对风险(RRa)为0.79(95%CI 0.71~0.87),IL-12/23抑制剂的RRa为0.69(95%CI 0.61~0.79)。
- IL-12/23抑制剂与IL-17抑制剂之间无显著差异(RRa 0.88,95%CI 0.76~1.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumour necrosis factor inhibitor (TNFi) agents are most often the first-choice biological treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed, a switch to another TNFi or to another therapeutic class may be considered. However, data supporting one approach over another are lacking. OBJECTIVE: To compare the long-term persistence of classes of biologics in PsA patients with prior TNFi exposure. METHODS: This nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database. We included all adults with PsA starting a second-line biological after discontinuing a TNFi during 2015-2020. Persistence was defined as the time from biological initiation to discontinuation and was estimated by the Kaplan-Meier method. Comparison of persistence by biological class was performed with Poisson regression models with time divided into 6-month intervals. RESULTS: We included 2975 patients: 1580 (53%) initiating a second TNFi, 426 (14%) an interleukin 12/23 inhibitor (IL-12/23i) and 969 (33%) an IL-17 inhibitor (IL-17i). Overall, 1-year and 3-year persistence rates were 42% and 17%, respectively. After adjustment, persistence was associated with treatment with an IL-17i (adjusted relative risk (RRa) 0.79, 95% CI 0.71 to 0.87) or IL-12/23i (RRa 0.69, 95% CI 0.61 to 0.79) vs a TNFi, with no significant difference between IL-12/23 and IL-17 inhibitors (RRa 0.88, 95% CI 0.76 to 1.02). CONCLUSIONS: Overall, this real-life study shows low persistence for all biologics at 3 years in PsA patients previously exposed to a TNFi. However, persistence was higher with an IL-17i or IL-12/23i than a TNFi.
引用
- Pina Vegas L, Hoisnard L, Bastard L, et al. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD Open. 2022. PMID: 36597983. doi:10.1136/rmdopen-2022-002681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。